Identification and evaluation of novel drug combinations of Aurora kinase inhibitor CCT137690 for enhanced efficacy in oral cancer cells

Cell Cycle. 2019 Sep;18(18):2281-2292. doi: 10.1080/15384101.2019.1643658. Epub 2019 Jul 26.


Oral cancer is the most prevalent subtype of head and neck cancers and arises mainly from squamous cells of the oral cavity. Patients with advanced metastatic disease have poor overall survival resulting primarily from limited treatment options. Recent advances in the understanding of molecular basis of oral tumorigenesis provide an opportunity for identification and validation of new drug targets. The deregulated expression of the Aurora family of mitotic kinases, for example, has been associated with pathogenesis and poor prognosis in oral cancer. Here, we have evaluated the efficacy of the pan-Aurora inhibitor (CCT137690) alone and in combination with different chemotherapeutic and targeted drugs to identify its synergistic partners in oral cancer cell lines (ORL-48 and ORL-115). CCT137690 effectively inhibits Aurora kinases in both the cell lines and displays potent antiproliferative activity towards them. Prolonged treatment of these cells with CCT137690 results in abrogated mitotic spindle formation, misaligned chromosome attachment and polyploidy that ultimately leads to apoptotic cell death. We further identified that inhibitors of EGFR (gefitinib) and PI3-kinase (pictilisib) synergize with CCT137690 to inhibit the proliferation of the oral cancer cell lines. Moreover, we demonstrate that polyethylene glycol-based nanocapsules harboring combinations of CCT137690 with gefitinib or pictilisib inhibit the growth of oral cancer cell lines in 3D spheroid cultures and induce apoptosis that is comparable to free drug combinations. In conclusion, we have demonstrated the in vitro efficacy of CCT137690 in oral cancer cell lines, identified novel drug combinations with CCT137690 and synthesized nanocapsules containing these drug combinations for co-administration.

Keywords: 3D spheroids; Aurora kinases; Oral cancer; drug combination; nanocapsules; nanoparticles.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents / pharmacology*
  • Apoptosis / drug effects
  • Aurora Kinase A / antagonists & inhibitors*
  • Aurora Kinase B / antagonists & inhibitors*
  • Cell Line, Tumor
  • Cell Proliferation / drug effects
  • Cell Survival / drug effects
  • Drug Combinations
  • Drug Evaluation, Preclinical / methods*
  • Drug Synergism
  • Drug Therapy, Combination
  • Gefitinib / pharmacology*
  • Humans
  • Imidazoles / pharmacology*
  • Indazoles / pharmacology*
  • Mouth Neoplasms / metabolism*
  • Mouth Neoplasms / pathology
  • Nanocapsules
  • Protein Kinase Inhibitors / pharmacology*
  • Pyridines / pharmacology*
  • Sulfonamides / pharmacology*


  • 2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine
  • 3-((4-(6-bromo-2-(4-(4-methylpiperazin-1-yl)phenyl)-3H-imidazo(4,5-b)pyridin-7-yl)piperazin-1-yl)methyl)-5-methylisoxazole
  • Antineoplastic Agents
  • Drug Combinations
  • Imidazoles
  • Indazoles
  • Nanocapsules
  • Protein Kinase Inhibitors
  • Pyridines
  • Sulfonamides
  • AURKA protein, human
  • AURKB protein, human
  • Aurora Kinase A
  • Aurora Kinase B
  • Gefitinib

Grants and funding

This work was supported by the Higher Education Commission, Pakistan [NRPU 5909].